Luma Group

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community. Who We AreOur flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence and, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. Beyond CapitalRA Capital offers its portfolio companies much more than capital to help them grow, make decisions, and succeed. We:Serve on boards of private and public companies and host board meetings at our offices Help recruit executives and board members Provide access to TechAtlas maps and expertise Prioritize indications and targets based on their feasibility and value given current scientific knowledge, unmet needs, and emerging competition Monitor for new applications and complementary technologies Create custom maps that lay out a company’s competition and unrealized opportunities Provide extra analytical bandwidth across our large team (e.g., analyze literature, provide insights from scientific and investor conferences) Assist with grant writing and preparation of scientific publications Interview clinicians and key opinion leaders (KOLs) Host advisory boards Facilitate partnership or acquisition discussions with larger companies Help design (or redesign) a corporate slide deck or website, leveraging in-house writing and graphics teams Make introductions to other investors Anchor subsequent financings and set the pace for closing Help select bankers for financings and M&A We also provide a growing suite of Innovator Resources to the broader ecosystem, with more hands-on support for our portfolio companies, management teams, and boards. These resources include: a comprehensive reference guide to conducting successful biotech board meetings; a data-driven guide to how to conduct a logical IPO based on first principles of price discovery and shareholder alignment; and a roadmap for how to convey your company’s unique Equity Value Proposition to employees (because they are also your investors). We’re available to coach you through a pitch, provide feedback on a deck, and partner with you to refine strategy or messaging at every stage. Additionally, we helped to found and continue to support No Patient Left Behind, a non-profit dedicated to promoting affordability of today’s medicines and the development of better ones. More specifically, NPLB advocates for insurance reforms that would allow all patients to afford the treatments they need, draws attention to the full societal value of all medicines and the merits of ensuring that all drugs go generic without delay, and educates lawmakers and the public about the workings of the biomedical ecosystem to protect it against misguided policies. Translation & HuntingRA Capital offers Executive-In-Residence (EIR) and venture partner programs for experienced professionals seeking thought partners. We welcome experienced drug hunters searching for technologies/candidates and looking to start new companies to collaborate with our team, explore the capabilities of our in-house incubator, and take advantage of the breadth and depth of our TechAtlas platform. RAVen, our in-house incubator, provides a collaborative platform for drug hunters and company builders to explore both the novel and the re-imagined. Discoveries and improvements in chemistry, molecular and cellular biology, and materials science create novel capabilities that may address unsolved challenges. Our understanding of fundamental biology is constantly evolving, revealing new applications for existing technologies and partially-developed drug candidates. Programs we consider worthwhile may form the basis for a new venture. We believe that when a business proposition is framed correctly, the capital markets have adequate resources and understanding to fund proper experimental design and solution development without forcing companies to cut corners. Furthermore, we have collaborated extensively with other funds that share our philosophy to enable ambitious and capital-intensive endeavors. Our ValuesWe at RA Capital are introspective and deliberate about the ways in which we engage with each other and those outside our firm. Our values represent a set of clear parameters by which we create working relationships founded on trust, collaboration, diligence, and integrity.We originate conviction. We do not borrow it from others. We expect and strive to inspire the best in everyone. We embrace the unfamiliar. We do not let convention stand in the way of what is right. We learn collaboratively. We have a bias for action. We are persistently curious and humbled by what is left to learn. We are data-driven and challenge assumptions. We preserve the ability to change our mind. We admit our mistakes and share lessons learned. We address the elephant in the room. We value our relationships and are positive, respectful, and open-minded. We take fun seriously.

Through our deep scientific and industry network we are able to identify transformative life science investments in under-ventured regions of the US and UK, building companies from scratch to create value and shared success. Our international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. We leverage our extensive relationships, industry operating experience and a disciplined investment approach to add significant value to our portfolio companies and to generate strong returns on investment for our investors. We believe in working closely with the management of our portfolio companies to drive the translation of their research into world-class businesses. Our global network includes investment professionals, scientists, industry executives, health practitioners, policy experts, regulatory advisors and business development leaders. This strong network contributes significantly to the growth and development of our portfolio companies.

DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease and related conditions. Together, we believe we can transform the future of patient care for the better. Our Strategy We aim to invest in, acquire, and co-develop products, solutions and businesses that improve care for patients with kidney disease and related conditions. PrioritiesCare Delivery Models: Advancements to expand access to care and improve clinical outcomes through adoption of tech-enabled services, home treatments and value-based care Life Sciences: Pharmaceuticals, medical devices and diagnostics that can improve clinical outcomes and patient experience while reducing costs Digital Health: Products and services that leverage technology, data and connectivity to improve care delivery

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

We back promising teams by providing both financial and business support to build the next generation of game-changing technologies companies in the field of Life Sciences. We invest in ambitious early stage start-ups and SMEs with innovative products globally, mainly across Europe and Israel. We bring strong entrepreneurial and financial expertise to portfolio companies well beyond just capital, relying on a wide network of clinicians and industry experts. We have established relationships with selected industrial partners to assist our founders in accelerating their development. We invest in people, believing that a strong and dedicated team is one of the most important factors in the success of our investments. We aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor. We invest for people, supporting the growth of companies and people that will reshape the medical world, answering real medical needs, saving lives and providing a better quality of life for patients and care-givers. An overall positive impact that will produce intrinsic value for both investors and society.

Santé is a leading early-stage venture capital firm founded in 2006, with offices in Austin and Boston. We invest at the intersection of science and technology, catalyzing disruptive opportunities across Biotech, MedTech and HealthTech. Combining extensive healthcare industry experience with deep scientific and technical expertise, we pursue innovative new opportunities to improve lives and generate returns. At Santé, we fuel entrepreneurs and form next-generation companies which shape the future of patient care, delivering better healthcare outcomes at a lower total cost to the system. Our expertise spans cellular biology, pharmaceutical drug development, device design and engineering, physician and hospital leadership, and public policy. Our investment philosophy of disciplined fund size, significant ownership positions, and diversified life sciences exposure has proven successful, as our funds have consistently generated top quartile returns for our investors. The firm has nearly $1BN under management and is investing out of Santé Health Ventures IV (a 2021 vintage fund) which follows the same successful investment strategy as our prior funds.